- Home
- AR vs BMRN Comparison
AR vs BMRN Comparison
Compare AR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AR
- BMRN
- Stock Information
- Founded
- AR 2002
- BMRN 1996
- Country
- AR United States
- BMRN United States
- Employees
- AR N/A
- BMRN N/A
- Industry
- AR Oil & Gas Production
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AR Energy
- BMRN Health Care
- Exchange
- AR Nasdaq
- BMRN Nasdaq
- Market Cap
- AR 9.9B
- BMRN 10.0B
- IPO Year
- AR 2013
- BMRN 1999
- Fundamental
- Price
- AR $31.88
- BMRN $53.49
- Analyst Decision
- AR Buy
- BMRN Buy
- Analyst Count
- AR 16
- BMRN 22
- Target Price
- AR $43.87
- BMRN $90.14
- AVG Volume (30 Days)
- AR 4.0M
- BMRN 2.6M
- Earning Date
- AR 10-29-2025
- BMRN 10-27-2025
- Dividend Yield
- AR N/A
- BMRN N/A
- EPS Growth
- AR 4491.03
- BMRN 60.52
- EPS
- AR 1.52
- BMRN 2.69
- Revenue
- AR $4,870,111,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- AR $24.16
- BMRN $13.35
- Revenue Next Year
- AR $6.58
- BMRN $9.18
- P/E Ratio
- AR $21.01
- BMRN $19.91
- Revenue Growth
- AR 11.79
- BMRN 12.39
- 52 Week Low
- AR $25.36
- BMRN $51.57
- 52 Week High
- AR $44.02
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- AR 45.31
- BMRN 47.03
- Support Level
- AR $31.66
- BMRN $52.26
- Resistance Level
- AR $33.06
- BMRN $53.94
- Average True Range (ATR)
- AR 1.13
- BMRN 1.65
- MACD
- AR -0.00
- BMRN 0.12
- Stochastic Oscillator
- AR 36.89
- BMRN 36.77
About AR Antero Resources Corporation
Antero Resources, based in Denver, explores for and produces natural gas and natural gas liquids in the United States and Canada. At the end of 2024, the company reported proven reserves of 17.9 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,424 million cubic feet of equivalent a day in 2024 at a ratio of 35% liquids and 65% natural gas.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.